Imagine living with a chronic lung condition that makes every breath a struggle, causing persistent coughing and mucus buildup. This is the reality for those with non-cystic fibrosis bronchiectasis (NCFB), a condition often overlooked but deeply impactful, especially for older adults. But here’s the groundbreaking news: the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved brensocatib (Brinsupri), the first-ever medication specifically designed to treat NCFB in patients aged 12 and older who’ve experienced frequent flare-ups in the past year. And this is the part most people miss—it’s not just about managing symptoms; it’s about targeting the root cause of inflammation in the lungs.
Brensocatib works by inhibiting dipeptidyl peptidase 1 (DPP1), a protein central to the inflammatory process in NCFB. By blocking DPP1, the medication aims to reduce lung flare-ups and potentially improve overall lung function. This is a significant leap forward, as Julian Beach, MHRA’s Executive Director of Healthcare Quality and Access, emphasized: ‘This is the first medicine licensed in the UK that specifically treats patients living with non-cystic fibrosis bronchiectasis.’ Yet, as with any new treatment, here’s where it gets controversial: while brensocatib offers hope, its long-term safety and effectiveness will remain under strict MHRA scrutiny, as is standard for all medications.
Taken once daily as a tablet, brensocatib’s side effects are worth noting. Common ones include nose and throat infections, diarrhea, vomiting, headaches, gum issues, skin thickening (hyperkeratosis), rashes, skin dryness, and even hair loss. Boldly speaking, these side effects might make some patients pause—is the trade-off worth it? The full list will be available in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC), published on the MHRA website within a week of approval.
If you suspect any side effects, don’t hesitate to consult your doctor, pharmacist, or nurse, and report them via the Yellow Card scheme (https://yellowcard.mhra.gov.uk/) or the MHRA Yellow Card app. This isn’t just about you—it’s about helping regulators monitor the drug’s real-world impact.
Granted on February 20, 2026, to Insmed Netherlands B.V., this marketing authorisation marks a new chapter in NCFB treatment. But here’s the thought-provoking question: As we celebrate this innovation, how do we balance hope with caution? Share your thoughts in the comments—do you think brensocatib will revolutionize NCFB treatment, or are its side effects a cause for concern? Let’s spark a conversation!
